SG11201602625YA - Vectors for expression of prostate-associated antigens - Google Patents
Vectors for expression of prostate-associated antigensInfo
- Publication number
- SG11201602625YA SG11201602625YA SG11201602625YA SG11201602625YA SG11201602625YA SG 11201602625Y A SG11201602625Y A SG 11201602625YA SG 11201602625Y A SG11201602625Y A SG 11201602625YA SG 11201602625Y A SG11201602625Y A SG 11201602625YA SG 11201602625Y A SG11201602625Y A SG 11201602625YA
- Authority
- SG
- Singapore
- Prior art keywords
- prostate
- vectors
- expression
- associated antigens
- antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361898966P | 2013-11-01 | 2013-11-01 | |
PCT/IB2014/065419 WO2015063647A1 (en) | 2013-11-01 | 2014-10-17 | Vectors for expression of prostate-associated antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201602625YA true SG11201602625YA (en) | 2016-05-30 |
Family
ID=51945953
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602625YA SG11201602625YA (en) | 2013-11-01 | 2014-10-17 | Vectors for expression of prostate-associated antigens |
SG10201910889VA SG10201910889VA (en) | 2013-11-01 | 2014-10-17 | Vectors for expression of prostate-associated antigens |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201910889VA SG10201910889VA (en) | 2013-11-01 | 2014-10-17 | Vectors for expression of prostate-associated antigens |
Country Status (27)
Country | Link |
---|---|
US (3) | US9402901B2 (en) |
EP (2) | EP3062815B1 (en) |
JP (3) | JP2016535989A (en) |
KR (2) | KR102196884B1 (en) |
CN (1) | CN105682679B (en) |
AR (2) | AR098256A1 (en) |
AU (2) | AU2014343321B2 (en) |
BR (1) | BR112016008806A2 (en) |
CA (1) | CA2928908C (en) |
DK (1) | DK3062815T3 (en) |
ES (1) | ES2715890T3 (en) |
HU (1) | HUE043042T2 (en) |
IL (1) | IL244897A0 (en) |
MX (2) | MX2016005656A (en) |
MY (2) | MY182168A (en) |
NZ (1) | NZ718652A (en) |
PE (1) | PE20171142A1 (en) |
PH (2) | PH12016500673B1 (en) |
PL (1) | PL3062815T3 (en) |
PT (1) | PT3062815T (en) |
RU (2) | RU2650860C2 (en) |
SA (1) | SA516371030B1 (en) |
SG (2) | SG11201602625YA (en) |
SI (1) | SI3062815T1 (en) |
TR (1) | TR201903074T4 (en) |
TW (2) | TWI572717B (en) |
WO (1) | WO2015063647A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE043042T2 (en) | 2013-11-01 | 2019-07-29 | Pfizer | Vectors for expression of prostate-associated antigens |
WO2015142963A1 (en) | 2014-03-17 | 2015-09-24 | Tapimmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
CN114209841A (en) | 2015-06-29 | 2022-03-22 | 维瑞斯特姆股份有限公司 | Therapeutic compositions, combinations and methods of use |
BR112018012374A2 (en) | 2015-12-16 | 2018-12-04 | Gritstone Oncology, Inc. | identification, manufacture and use of neoantigen |
TWI654302B (en) | 2016-01-19 | 2019-03-21 | 輝瑞股份有限公司 | Cancer vaccine |
EP3408394B1 (en) * | 2016-01-27 | 2020-08-12 | Total Raffinage Chimie | Multigene expression in microalgae |
CN109312364A (en) * | 2016-03-18 | 2019-02-05 | 河谷细胞有限公司 | For infecting the multi-mode carrier of Dendritic Cells |
EP3452081A1 (en) * | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
CA3026342A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
WO2018069316A2 (en) * | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
MA46904A (en) * | 2016-11-23 | 2019-10-02 | Gritstone Oncology Inc | VIRAL ADMINISTRATION OF NEO-ANTIGENS |
CA3056090A1 (en) | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
TW201907937A (en) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | Alpha virus new antigen vector |
CN111065408A (en) | 2017-07-11 | 2020-04-24 | 辉瑞公司 | Immunogenic compositions |
CA3078744A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
AU2018373154A1 (en) | 2017-11-22 | 2020-07-02 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
KR20200118029A (en) | 2018-01-04 | 2020-10-14 | 아이코닉 테라퓨틱스, 인코포레이티드 | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
CN114072516A (en) | 2019-05-30 | 2022-02-18 | 磨石生物公司 | Modified adenoviruses |
RU2726541C1 (en) * | 2019-11-19 | 2020-07-14 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | Recombinant human breast cancer cell line brcch4e-134, expressing human prostate-specific membrane antigen |
CN113088530A (en) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | Expression vector based on chimpanzee ChAd63 adenovirus and construction method thereof |
CN116438308A (en) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | Multi-epitope vaccine box |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US628371A (en) | 1898-09-10 | 1899-07-04 | Clark W Thomas | Machine for making berry-boxes. |
JPS58130841A (en) * | 1982-01-29 | 1983-08-04 | Nec Corp | Luminescent mark detection device |
US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
DE69841122D1 (en) | 1997-03-10 | 2009-10-15 | Coley Pharm Gmbh | Use of non-methylated CpG dinucleotide in combination with aluminum as adjuvants |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
EP2085090A3 (en) | 1997-06-06 | 2012-05-02 | The Regents of the University of California | Inhibitors of DNA immunostimulatory sequence activity |
EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
OA11917A (en) | 1998-12-23 | 2006-04-13 | Abgenix Inc | Human monoclonal antibodies to ctla-4. |
EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
EP1159429A2 (en) | 1999-02-18 | 2001-12-05 | Compugen Ltd. | Psa and klk-2 splicing variants |
CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
WO2001016180A2 (en) | 1999-08-27 | 2001-03-08 | Board Of Regents, The University Of Texas System | Cd40 agonist compositions and methods of use |
ATE369359T1 (en) | 2000-02-15 | 2007-08-15 | Sugen Inc | PYRROLE SUBSTITUTED INDOLIN-2-ONE PROTEIN KINASE INHIBITORS |
EP1276896B1 (en) * | 2000-04-28 | 2010-07-21 | Mannkind Corporation | Epitope synchronization in antigen presenting cells |
RU2192889C1 (en) * | 2001-03-16 | 2002-11-20 | Эпштейн Олег Ильич | Medicinal preparation and method for treating prostatic diseases |
ES2340499T3 (en) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | TUMOR ANTIGEN ARNM STABILIZED WITH AN INCREASED G / C CONTENT. |
BR0210586A (en) | 2001-06-22 | 2005-07-12 | Wistar Inst | Methods for inducing a cytotoxic immune reaction and useful recombinant simian adenovirus compositions thereof |
ATE530672T1 (en) | 2001-06-22 | 2011-11-15 | Univ Pennsylvania | RECOMBINANT ADENOVIRUSES WITH MONKEY ADENOVIRUS PROTEINS AND USE THEREOF. |
JP4302513B2 (en) | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Polynucleotides encoding antigenic type B HIV polypeptides and / or antigenic type C HIV polypeptides, polypeptides thereof and uses thereof |
JP5033303B2 (en) * | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Polynucleotides encoding polypeptides with antigenic type C HIV, polypeptides and uses thereof |
CN100439360C (en) | 2001-08-15 | 2008-12-03 | 法玛西雅厄普约翰美国公司 | Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof |
BR0206112A (en) * | 2001-10-10 | 2005-05-10 | Centocor Inc | Nucleic acid vaccines using tumor antigen-encoding nucleic acids with cytokine helper-encoding nucleic acid |
TWI228718B (en) | 2001-11-05 | 2005-03-01 | Tdk Corp | Manufacturing method and device of mold plate for information medium |
SG165153A1 (en) * | 2001-11-21 | 2010-10-28 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP1476443A2 (en) | 2002-02-15 | 2004-11-17 | PHARMACIA & UPJOHN COMPANY | Process for preparing indolinone derivatives |
TW200418836A (en) | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
WO2004067570A2 (en) | 2003-01-28 | 2004-08-12 | Proscan Rx Pharma | Prostate cancer diagnosis and treatment |
ATE541052T1 (en) * | 2003-05-30 | 2012-01-15 | Agensys Inc | VARIANTS OF PROSTATE STEM CELL ANTIGEN (PSCA) AND PARTIAL SEQUENCES THEREOF |
DE10335833A1 (en) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfection of blood cells with mRNA for immune stimulation and gene therapy |
WO2005023765A1 (en) | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
CA2993042A1 (en) * | 2004-01-23 | 2005-08-04 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
ES2361000T3 (en) | 2004-04-28 | 2011-06-13 | The Trustees Of The University Of Pennsylvania | SEQUENTIAL SUPPLY OF IMMUNOGENIC MOLECULES THROUGH ADMINISTRATIONS OF AN ADENOVIRUS AND AN ADENO-ASSOCIATED VIRUS. |
DE102004035227A1 (en) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA mixture for vaccination against tumor diseases |
JP5405110B2 (en) | 2005-09-19 | 2014-02-05 | ベリデックス・エルエルシー | Methods and materials for identifying primary lesions of cancer of unknown primary |
EP1954311A4 (en) | 2005-12-07 | 2009-12-23 | Medarex Inc | Ctla-4 antibody dosage escalation regimens |
RS51250B (en) | 2006-04-28 | 2010-12-31 | The Trustees Of The University Of Pennsylvania | Modified adenovirus hexon protein and uses thereof |
GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
WO2009046739A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
EP2207564B1 (en) * | 2007-10-18 | 2016-10-05 | Bavarian Nordic A/S | Use of mva to treat prostate cancer |
IN2012DN02368A (en) * | 2009-09-14 | 2015-08-21 | Baylor Res Insitute | |
EP3909973A3 (en) * | 2010-11-12 | 2022-01-26 | The Trustees Of The University Of Pennsylvania | Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof |
WO2012116714A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
EA027236B1 (en) * | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
CN102294025B (en) * | 2011-08-10 | 2013-06-05 | 中国人民解放军第三军医大学第三附属医院 | Compound of prostate stem cell antigen polypeptide and nucleic acid and preparation method and application thereof |
SG10201603896RA (en) * | 2012-05-04 | 2016-07-28 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
HUE043042T2 (en) | 2013-11-01 | 2019-07-29 | Pfizer | Vectors for expression of prostate-associated antigens |
-
2014
- 2014-10-17 HU HUE14802175A patent/HUE043042T2/en unknown
- 2014-10-17 RU RU2016114416A patent/RU2650860C2/en active
- 2014-10-17 CN CN201480059609.4A patent/CN105682679B/en not_active Expired - Fee Related
- 2014-10-17 DK DK14802175.1T patent/DK3062815T3/en active
- 2014-10-17 AU AU2014343321A patent/AU2014343321B2/en not_active Ceased
- 2014-10-17 EP EP14802175.1A patent/EP3062815B1/en active Active
- 2014-10-17 MY MYPI2016701396A patent/MY182168A/en unknown
- 2014-10-17 ES ES14802175T patent/ES2715890T3/en active Active
- 2014-10-17 TR TR2019/03074T patent/TR201903074T4/en unknown
- 2014-10-17 NZ NZ718652A patent/NZ718652A/en not_active IP Right Cessation
- 2014-10-17 SG SG11201602625YA patent/SG11201602625YA/en unknown
- 2014-10-17 WO PCT/IB2014/065419 patent/WO2015063647A1/en active Application Filing
- 2014-10-17 MY MYPI2020007026A patent/MY196581A/en unknown
- 2014-10-17 RU RU2018108259A patent/RU2018108259A/en unknown
- 2014-10-17 EP EP18207060.7A patent/EP3524262A1/en not_active Withdrawn
- 2014-10-17 BR BR112016008806A patent/BR112016008806A2/en not_active IP Right Cessation
- 2014-10-17 MX MX2016005656A patent/MX2016005656A/en active IP Right Grant
- 2014-10-17 KR KR1020197021909A patent/KR102196884B1/en active IP Right Grant
- 2014-10-17 KR KR1020167014145A patent/KR102006527B1/en active IP Right Grant
- 2014-10-17 SG SG10201910889VA patent/SG10201910889VA/en unknown
- 2014-10-17 PL PL14802175T patent/PL3062815T3/en unknown
- 2014-10-17 PT PT14802175T patent/PT3062815T/en unknown
- 2014-10-17 SI SI201431100T patent/SI3062815T1/en unknown
- 2014-10-17 PE PE2016000569A patent/PE20171142A1/en unknown
- 2014-10-17 JP JP2016526872A patent/JP2016535989A/en active Pending
- 2014-10-17 CA CA2928908A patent/CA2928908C/en active Active
- 2014-10-29 US US14/527,226 patent/US9402901B2/en active Active
- 2014-10-29 TW TW103137445A patent/TWI572717B/en not_active IP Right Cessation
- 2014-10-29 TW TW105139927A patent/TWI650418B/en not_active IP Right Cessation
- 2014-11-03 AR ARP140104090A patent/AR098256A1/en active IP Right Grant
-
2016
- 2016-04-04 IL IL244897A patent/IL244897A0/en unknown
- 2016-04-12 PH PH12016500673A patent/PH12016500673B1/en unknown
- 2016-04-28 SA SA516371030A patent/SA516371030B1/en unknown
- 2016-04-29 MX MX2020001813A patent/MX2020001813A/en unknown
- 2016-05-04 US US15/146,578 patent/US10092636B2/en active Active
-
2018
- 2018-08-23 US US16/111,120 patent/US11173196B2/en active Active
-
2019
- 2019-07-05 JP JP2019125723A patent/JP6621560B2/en not_active Expired - Fee Related
- 2019-11-19 JP JP2019208986A patent/JP7014764B2/en active Active
-
2020
- 2020-03-25 AU AU2020202114A patent/AU2020202114A1/en not_active Abandoned
- 2020-04-17 AR ARP200101097A patent/AR118725A2/en unknown
- 2020-10-08 PH PH12020551666A patent/PH12020551666A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL244897A0 (en) | Vectors for expression of prostate-associated antigens | |
IL269528A (en) | Anti-fcrh5 antibodies | |
HK1217023A1 (en) | Novel antibodies | |
GB201322583D0 (en) | Antibodies | |
HK1220142A1 (en) | Antibodies | |
GB201308658D0 (en) | Antibodies | |
GB201315486D0 (en) | Antibodies | |
IL245488A0 (en) | Anti-ccl17 antibodies | |
AU2013901426A0 (en) | Identification of Epitopes | |
GB201318283D0 (en) | Antibodies |